{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T22:44:52Z","timestamp":1770072292672,"version":"3.49.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC2406900"],"award-info":[{"award-number":["2022YFC2406900"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC2406904"],"award-info":[{"award-number":["2022YFC2406904"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicalradiologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Radiology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.crad.2025.107038","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T06:31:33Z","timestamp":1753857093000},"page":"107038","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Characteristics of the 18F-fluorodeoxyglucose (18F-FDG) and [18F] 9-fluoropropyl-(+)-dihydrotetrabenazine (18F-FP-DTBZ) positron emission tomography (PET) in patients with cognitive impairment in Parkinson's disease"],"prefix":"10.1016","volume":"89","author":[{"given":"S.","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0425-3921","authenticated-orcid":false,"given":"J.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.crad.2025.107038_bib1","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S1474-4422(21)00030-2","article-title":"Challenges in the diagnosis of Parkinson's disease","volume":"20","author":"Tolosa","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.crad.2025.107038_bib2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41572-021-00280-3","article-title":"Parkinson disease-associated cognitive impairment","volume":"7","author":"Aarsland","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.crad.2025.107038_bib3","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nrneurol.2017.27","article-title":"Cognitive decline in Parkinson disease","volume":"13","author":"Aarsland","year":"2017","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.crad.2025.107038_bib4","doi-asserted-by":"crossref","DOI":"10.1002\/gps.5955","article-title":"Global assessment, cognitive profile, and characteristics of mild cognitive impairment in Parkinson's disease","volume":"38","author":"Yang","year":"2023","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1016\/j.crad.2025.107038_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18030551","article-title":"Parkinson's disease: from pathogenesis to pharmacogenomics","volume":"18","author":"Cacabelos","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.crad.2025.107038_bib6","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1136\/jnnp-2011-301818","article-title":"Functional brain imaging of cognitive dysfunction in Parkinson's disease","volume":"83","author":"Hirano","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.crad.2025.107038_bib7","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2967\/jnumed.113.121897","article-title":"In vivo detection of monoaminergic degeneration in early Parkinson disease by (18)F-9-fluoropropyl-(+)-dihydrotetrabenzazine PET","volume":"55","author":"Lin","year":"2014","journal-title":"J Nucl Med"},{"key":"10.1016\/j.crad.2025.107038_bib8","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1001\/jamaneurol.2014.2757","article-title":"Frequency of cholinergic and caudate nucleus dopaminergic deficits across the predemented cognitive spectrum of Parkinson disease and evidence of interaction effects","volume":"72","author":"Bohnen","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.crad.2025.107038_bib9","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1007\/s00259-015-3039-0","article-title":"Brain (18)F-DOPA PET and cognition in de novo Parkinson's disease","volume":"42","author":"Picco","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.crad.2025.107038_bib10","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.parkreldis.2018.02.048","article-title":"Effect of striatal dopamine depletion on cognition in de novo Parkinson's disease","volume":"51","author":"Chung","year":"2018","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.crad.2025.107038_bib11","doi-asserted-by":"crossref","DOI":"10.1172\/JCI157074","article-title":"Predicting cognitive decline in Parkinson's disease using FDG-PET-based supervised learning","volume":"132","author":"Booth","year":"2022","journal-title":"J Clin Invest"},{"key":"10.1016\/j.crad.2025.107038_bib12","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1212\/WNL.0b013e3182315259","article-title":"Mild cognitive impairment in drug-naive patients with PD is associated with cerebral hypometabolism","volume":"77","author":"Pappat\u00e0","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.crad.2025.107038_bib13","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s11065-021-09502-7","article-title":"Meta-analysis of cognition in Parkinson's disease mild cognitive impairment and dementia progression","volume":"32","author":"Wallace","year":"2022","journal-title":"Neuropsychol Rev"},{"key":"10.1016\/j.crad.2025.107038_bib14","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson's disease","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov Disord"},{"key":"10.1016\/j.crad.2025.107038_bib15","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1002\/mds.27362","article-title":"Validation of the MDS clinical diagnostic criteria for Parkinson's disease","volume":"33","author":"Postuma","year":"2018","journal-title":"Mov Disord"},{"key":"10.1016\/j.crad.2025.107038_bib16","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/mds.24893","article-title":"Diagnostic criteria for mild cognitive impairment in Parkinson's disease: movement Disorder Society Task Force guidelines","volume":"27","author":"Litvan","year":"2012","journal-title":"Mov Disord"},{"key":"10.1016\/j.crad.2025.107038_bib17","article-title":"Delayed (18)F-FDG PET imaging provides better metabolic asymmetry in potential epileptogenic zone in temporal lobe epilepsy","volume":"10","author":"Hong","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.crad.2025.107038_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.nicl.2023.103555","article-title":"Relationship of irisin with disease severity and dopamine uptake in Parkinson's disease patients","volume":"41","author":"Shi","year":"2024","journal-title":"Neuroimage Clin"},{"key":"10.1016\/j.crad.2025.107038_bib19","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1001\/jamaneurol.2014.290","article-title":"Correlation of Parkinson disease severity and 18F-DTBZ positron emission tomography","volume":"71","author":"Hsiao","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.crad.2025.107038_bib20","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1136\/jnnp-2016-313918","article-title":"Cerebral glucose metabolism and cognition in newly diagnosed Parkinson's disease: ICICLE-PD study","volume":"88","author":"Firbank","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.crad.2025.107038_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0279007","article-title":"Mirror writing and cortical hypometabolism in Parkinson's disease","volume":"17","author":"Shinohara","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.crad.2025.107038_bib22","doi-asserted-by":"crossref","first-page":"4652","DOI":"10.1002\/hbm.24311","article-title":"Clinical characteristics of cognitive impairment in patients with Parkinson's disease and its related pattern in (18) F-FDG PET imaging","volume":"39","author":"Wu","year":"2018","journal-title":"Hum Brain Mapp"},{"key":"10.1016\/j.crad.2025.107038_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25010498","article-title":"Pathobiology of cognitive impairment in Parkinson disease: challenges and outlooks","volume":"25","author":"Jellinger","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.crad.2025.107038_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2021.627356","article-title":"Dopaminergic and metabolic correlations with cognitive domains in non-demented Parkinson's disease","volume":"13","author":"Han","year":"2021","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.crad.2025.107038_bib25","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/bs.irn.2017.05.002","article-title":"Cognition in Parkinson's disease","volume":"133","author":"O'Callaghan","year":"2017","journal-title":"Int Rev Neurobiol"},{"key":"10.1016\/j.crad.2025.107038_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2020.117177","article-title":"Cognitive impairment in Parkinson's disease: a clinical and pathophysiological overview","volume":"419","author":"Brand\u00e3o","year":"2020","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.crad.2025.107038_bib27","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.neuropsychologia.2006.01.026","article-title":"Sex differences in visuo-spatial processing: an fMRI study of mental rotation","volume":"44","author":"Hugdahl","year":"2006","journal-title":"Neuropsychologia"},{"key":"10.1016\/j.crad.2025.107038_bib28","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S1474-4422(13)70123-6","article-title":"Exercise-enhanced neuroplasticity targeting motor and cognitive circuitry in Parkinson's disease","volume":"12","author":"Petzinger","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.crad.2025.107038_bib29","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.2967\/jnumed.116.186403","article-title":"(18)F-FDG PET in Parkinsonism: differential diagnosis and evaluation of cognitive impairment","volume":"58","author":"Meyer","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1016\/j.crad.2025.107038_bib30","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jns.2016.11.068","article-title":"Longitudinal study of cognitive and cerebral metabolic changes in Parkinson's disease","volume":"372","author":"Baba","year":"2017","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.crad.2025.107038_bib31","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3389\/fneur.2020.00047","article-title":"Imaging mild cognitive impairment and dementia in Parkinson's disease","volume":"11","author":"Sasikumar","year":"2020","journal-title":"Front Neurol"},{"key":"10.1016\/j.crad.2025.107038_bib32","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1126\/science.aaz5891","article-title":"Dopamine promotes cognitive effort by biasing the benefits versus costs of cognitive work","volume":"367","author":"Westbrook","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.crad.2025.107038_bib33","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1177\/1073858415602850","article-title":"Doping the mind: dopaminergic modulation of prefrontal cortical cognition","volume":"22","author":"Ranganath","year":"2016","journal-title":"Neuroscientist"}],"container-title":["Clinical Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009926025002430?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009926025002430?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T16:52:33Z","timestamp":1758905553000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009926025002430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":33,"alternative-id":["S0009926025002430"],"URL":"https:\/\/doi.org\/10.1016\/j.crad.2025.107038","relation":{},"ISSN":["0009-9260"],"issn-type":[{"value":"0009-9260","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characteristics of the 18F-fluorodeoxyglucose (18F-FDG) and [18F] 9-fluoropropyl-(+)-dihydrotetrabenazine (18F-FP-DTBZ) positron emission tomography (PET) in patients with cognitive impairment in Parkinson's disease","name":"articletitle","label":"Article Title"},{"value":"Clinical Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.crad.2025.107038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Royal College of Radiologists. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107038"}}